This brand name is authorized in Italy.
The drug ZOPRAZIDE contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
88ZQ329PU2 - ZOFENOPRIL CALCIUM
|
|
The beneficial effects of zofenopril in hypertension and acute myocardial infarction appear to result primarily from the suppression of the plasma renin-angiotensin aldosterone system. Inhibition of ACE (Ki 0.4nM in rabbit lung for arginine salt of zofenoprilat) results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. |
|
2
|
UNII
0J48LPH2TH - HYDROCHLOROTHIAZIDE
|
|
Hydrochlorothiazide is a diuretic with antihypertensive properties. It acts by inhibiting the renal tubular re-absorption of sodium and chloride ions, which are excreted with an accompanying volume of water. Potassium excretion is also promoted. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| C09BA15 | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09B ACE inhibitors, combinations → C09BA ACE inhibitors and diuretics | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| IT | Agenzia del Farmaco | 036702025 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.